Joule’s CO2-Recycled Ethanol Meets U.S. and European Specifications

Joule’s CO2-Recycled Ethanol Meets U.S. and European Specifications

May 11, 2015

Bedford, Mass. – May 11, 2015 – Joule, the pioneer of liquid fuels from recycled CO2, today announced the successful results from third-party testing of its ethanol fuel, setting the stage to obtain certification for commercial use. Initiated by AUDI, Joule’s strategic partner in the automotive space, the test results confirm that Joule’s ethanol meets the following standards in the U.S. and Europe, respectively:  

Concert Pharmaceuticals Reports First Quarter 2015 Financial Results

Concert Pharmaceuticals Reports First Quarter 2015 Financial Results

May 8, 2015

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2015.

Eleven Biotherapeutics Presents Clinical Data on EBI-005 for the Treatment of Dry Eye Disease and Allergic Conjunctivitis at ARVO 2015 Annual Meeting

Eleven Biotherapeutics Presents Clinical Data on EBI-005 for the Treatment of Dry Eye Disease and Allergic Conjunctivitis at ARVO 2015 Annual Meeting

May 7, 2015

Clinically Relevant, Statistically Significant Improvements of Symptoms in the Late Phase of Allergic Conjunctivitis Supports Advancing to a Phase 3 Natural Environment Study

BIND Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update

BIND Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update

May 7, 2015

-First Patient Dosed in Squamous Histology Cohort and Enrollment On-track in KRAS Mutant Cohort of iNSITE 1 Clinical Trial in NSCLC-

-Milestone Achieved in Collaboration with AstraZeneca and Second Accurin Candidate, AZD2811, Expected to Enter Clinic in 2H2015-

- Management to host conference call today at 8:30 a.m. EDT -

Agios Reports First Quarter 2015 Financial Results and Outlines Late-Stage Clinical Development for AG-221 and AG-120

Agios Reports First Quarter 2015 Financial Results and Outlines Late-Stage Clinical Development for AG-221 and AG-120

May 7, 2015
  • AG-221: Ongoing Phase 1 study expanded by an additional 125 patients in selected AML (acute myeloid leukemia) populations
  • AG-120: Ongoing Phase 1 hematologic malignancy study expanded by 175 patients in three cohorts, including 125 patients in a defined AML population
  • EHA: Abstracts for three lead clinical programs accepted for presentation at the 20th Congress of the European Hematology Association (EHA)

Acceleron Pharma Reports First Quarter 2015 Financial and Operational Results

Acceleron Pharma Reports First Quarter 2015 Financial and Operational Results

May 7, 2015

– Luspatercept phase 2 data showed encouraging activity in lower risk myelodysplastic syndromes (MDS) patients –

– Celgene and Acceleron selected luspatercept to advance into Phase 3 programs in MDS and beta-thalassemia by year-end –

– Promising data from dalantercept phase 2 clinical trial in patients with renal cell carcinoma presented at ASCO-GU conference – 

T2 Biosystems Reports 2015 First Quarter Results

T2 Biosystems Reports 2015 First Quarter Results

May 5, 2015

LEXINGTON, Mass., May 5, 2015 (GLOBE NEWSWIRE) -- T2 Biosystems (Nasdaq:TTOO) today reported operating highlights and financial results for the first quarter ended March 31, 2015. Recent operational highlights included:

Eleven Biotherapeutics Presents Data on EBI-031 for the Treatment of Diabetic Macular Edema at ARVO 2015 Annual Meeting

Eleven Biotherapeutics Presents Data on EBI-031 for the Treatment of Diabetic Macular Edema at ARVO 2015 Annual Meeting

May 5, 2015

Preclinical Data on EBI-031 Demonstrates Potent IL-6 Inhibition and Extended Vitreal Retention

Editas Medicine Announces Six Scientific Presentations at the American Society of Gene And Cell Therapy 18th Annual Meeting

Editas Medicine Announces Six Scientific Presentations at the American Society of Gene And Cell Therapy 18th Annual Meeting

May 6, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a leading genome editing company, today announced six abstracts have been accepted for one oral and five poster presentations at the 18th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). The presentations will detail data from research programs across a broad range of disease areas, including cancer, hematologic (blood) and ophthalmic (eye) diseases. The meeting will take place May 13-16 at the Hyatt Regency in New Orleans. Following is a schedule of Editas’ poster and oral presentations:

Flagship Ventures Forms Strategic Innovation Partnerships with AstraZeneca, Nestlé Health Science and Bayer CropScience

Flagship Ventures Forms Strategic Innovation Partnerships with AstraZeneca, Nestlé Health Science and Bayer CropScience

May 5, 2015

Scaling Entrepreneurial Innovations in Life Sciences